NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

美國前列腺癌治療設備市場調查報告:按類型(放射/外科/高密度聚焦超音波(HIFU)/冷凍療法),最終用戶(醫院/專科中心)-行業分析和到2030年的增長預測

U.S. Prostate Cancer Treatment Device Market Research Report: By Type (Radiation, Surgery, High-Intensity Focused Ultrasound, Cryotherapy), End User (Hospitals, Specialty Centers) - Industry Analysis and Growth Forecast to 2030

出版商 Prescient & Strategic Intelligence Private Limited 商品編碼 971139
出版日期 內容資訊 英文 124 Pages
商品交期: 2-3個工作天內
價格
美國前列腺癌治療設備市場調查報告:按類型(放射/外科/高密度聚焦超音波(HIFU)/冷凍療法),最終用戶(醫院/專科中心)-行業分析和到2030年的增長預測 U.S. Prostate Cancer Treatment Device Market Research Report: By Type (Radiation, Surgery, High-Intensity Focused Ultrasound, Cryotherapy), End User (Hospitals, Specialty Centers) - Industry Analysis and Growth Forecast to 2030
出版日期: 2020年09月01日內容資訊: 英文 124 Pages
簡介

預計到2030年,美國前列腺癌治療設備市場的規模將從2019年的9590萬美元增長至1.571億美元,在2020年至2030年的預測期內達到5.6%。預計將以CAGR增長。市場增長的主要驅動力是該國記錄的前列腺癌病例數量逐年增加。

本報告對美國前列腺癌治療儀市場進行了調查和分析,並系統地提供了市場概況,影響市場增長的因素,市場規模和預測,按細分市場分析,競爭狀況等。

目錄

第1章調查背景

  • 調查目的
  • 市場定義
  • 調查範圍
    • 市場細分:按類型
    • 市場細分:按最終用戶劃分
    • 市場細分:按州
    • 分析期間
    • 市場數據報告單位
  • 主要利益相關者

第2章調查方法

  • 二次調查
  • 初步調查
  • 基線調查方法
  • 市場規模估計
  • 數據三角剖分
  • 調查的先決條件

第3章執行摘要

第4章簡介

  • 市場細分的定義
    • 按類型
      • 輻射
      • 手術
      • HIFU
      • 冷凍療法
      • 其他
    • 最終用戶
      • 醫院
      • 專科中心
      • 其他
  • 市場動態
    • 趨勢
      • 採用機器人前列腺切除術
      • 加速放射治療技術的發展
    • 促進因素
      • 技術進步
      • 前列腺癌的患病率增加
      • 越來越多的政府舉措
      • 老年人口迅速增加
      • 分析增長因素對市場預測的影響
    • 抑制因素
      • 前列腺癌器械的批准期長
      • 確定放射治療反應的分子預測因子方面的挑戰
      • 分析限制因素對市場預測的影響
    • 市場機會
      • 定位裝置可改善治療和患者體驗
  • COVID-19對美國前列腺癌治療設備市場的影響
    • 供應方分析
    • 需求側分析
  • 波特的五力分析
  • 治療比較
    • HIFU治療
    • 外科手術與放射治療
    • 冷凍療法
  • 設備平均價格

第五章美國市場規模和預測

  • 按類型
  • 最終用戶
  • 按州

第6章競爭情況

  • 主要公司的競爭基準
  • 市場戰略發展

第7章公司簡介

  • SonaCare Medical LLC
  • EDAP TMS SA
  • Profound Medical Corporation
  • Eckert & Ziegler AG
  • HealthTronics Inc.
  • Boston Scientific Corporation
  • Elekta AB
  • Accuray Incorporated
  • Varian Medical Systems Inc.
  • Becton, Dickinson and Company
  • Intuitive Surgical Inc.
  • ViewRay Inc.
  • Provision Healthcare
  • Isoray Inc.
  • Theragenics Corporation

第8章附錄

目錄
Product Code: LS12077

The U.S. prostate cancer treatment devices market attained a value of $95.9 million in 2019 and is predicted to grow at a CAGR of 5.6% between 2020 and 2030. According to the forecast of P&S Intelligence, a market research firm based in India, the market would reach a valuation of $157.1 million by 2030. The main factors driving the progress of the market are the increasing number of prostate cancer cases being recorded in the country every year.

The high prevalence of this diseases is predicted to push up the demand for various treatment devices and equipment such as cryotherapy, surgery, and radiotherapy in the future years, thereby causing the expansion of the U.S. prostate cancer treatment devices market. Apart from this, the increasing number of government initiatives being implemented in the country is also fueling the market advancement. The federal government spends a huge portion of the country's GDP on healthcare every year.

As per the reports of the National Health Expenditure Accounts (NHEA), healthcare expenditure in the U.S. increased by as much as 4.3% and reached $3.3 trillion in 2016. This percentage further grew to 5.4% in 2017. The soaring healthcare expenditure is making the management and treatment of various diseases more affordable than they were before, which is, in turn, fueling the expansion of the U.S. prostate cancer treatment devices market.

Thus, it can be said with certainty that the market would demonstrate substantial growth in the upcoming years, mainly because of the rising incidence of prostate cancer and the surging government spending on healthcare in the country.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Type
    • 1.3.2 Market Segmentation by End User
    • 1.3.3 Market Segmentation by State
    • 1.3.4 Analysis Period
    • 1.3.5 Market Data Reporting Unit
      • 1.3.5.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Split of Primary Research Information
    • 2.2.2 Breakdown of Primary Research by Industry Participant
    • 2.2.3 Breakdown of Primary Research by company type
    • 2.2.4 Breakdown of Primary Research by Company and Designation
  • 2.3 Baseline Methodology
  • 2.4 Market Size Estimation
  • 2.5 Data Triangulation
  • 2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Type
      • 4.1.1.1 Radiation
        • 4.1.1.1.1 Clinical trials
      • 4.1.1.2 Surgery
        • 4.1.1.2.1 Clinical trials
      • 4.1.1.3 HIFU
        • 4.1.1.3.1 Clinical trials
      • 4.1.1.4 Cryotherapy
        • 4.1.1.4.1 Clinical trials
      • 4.1.1.5 Others
    • 4.1.2 By End User
      • 4.1.2.1 Hospitals
      • 4.1.2.2 Specialty centers
      • 4.1.2.3 Others
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Adoption of robotic prostatectomy
      • 4.2.1.2 Accelerating evolution in radiotherapy techniques
    • 4.2.2 Drivers
      • 4.2.2.1 Technological advancements
      • 4.2.2.2 Increasing prevalence of prostate cancer
      • 4.2.2.3 Rising number of government initiatives
      • 4.2.2.4 Surging geriatric population
      • 4.2.2.5 Impact analysis of drivers on market forecast
    • 4.2.3 Restraints
      • 4.2.3.1 Longer approval time for prostate cancer devices
      • 4.2.3.2 Challenges in identifying molecular predictors of response to radiotherapy
      • 4.2.3.3 Impact analysis of drivers on market forecast
    • 4.2.4 Opportunities
      • 4.2.4.1 Positioning devices to improve treatment and patient experience
  • 4.3 COVID-19 Impact on U.S. Prostate Cancer Treatment Devices Market
    • 4.3.1 Supply Side Analysis
    • 4.3.2 Demand Side Analysis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Intensity of Rivalry
    • 4.4.4 Threat of New Entrants
    • 4.4.5 Threat of Substitutes
  • 4.5 Therapy Comparison
    • 4.5.1 HIFU Therapy
    • 4.5.2 Surgery Vs Radiation Therapy
    • 4.5.3 Cryotherapy
  • 4.6 Average Pricing of Devices

Chapter 5. U.S. Market Size and Forecast

  • 5.1 By Type
  • 5.2 By End User
  • 5.3 By State

Chapter 6. Competitive Landscape

  • 6.1 Product Benchmarking of Key Players
  • 6.2 Strategic Developments of Key Players
    • 6.2.1 Approvals and Product Launch
    • 6.2.2 Mergers and Acquisitions
    • 6.2.3 Other Developments

Chapter 7. Company Profiles

  • 7.1 SonaCare Medical LLC
    • 7.1.1 Business Overview
    • 7.1.2 Product and Service Offerings
  • 7.2 EDAP TMS SA
    • 7.2.1 Business Overview
    • 7.2.2 Product and Service Offerings
    • 7.2.3 Key Financial Summary
  • 7.3 Profound Medical Corporation
    • 7.3.1 Business Overview
    • 7.3.2 Product and Service Offerings
    • 7.3.3 Key Financial Summary
  • 7.4 Eckert & Ziegler AG
    • 7.4.1 Business Overview
    • 7.4.2 Product and Service Offerings
    • 7.4.3 Key Financial Summary
  • 7.5 HealthTronics Inc.
    • 7.5.1 Business Overview
    • 7.5.2 Product and Service Offerings
  • 7.6 Boston Scientific Corporation
    • 7.6.1 Business Overview
    • 7.6.2 Product and Service Offerings
    • 7.6.3 Key Financial Summary
  • 7.7 Elekta AB
    • 7.7.1 Business Overview
    • 7.7.2 Product and Service Offerings
    • 7.7.3 Key Financial Summary
  • 7.8 Accuray Incorporated
    • 7.8.1 Business Overview
    • 7.8.2 Product and Service Offerings
    • 7.8.3 Key Financial Summary
  • 7.9 Varian Medical Systems Inc.
    • 7.9.1 Business Overview
    • 7.9.2 Product and Service Offerings
    • 7.9.3 Key Financial Summary
  • 7.10 Becton, Dickinson and Company
    • 7.10.1 Business Overview
    • 7.10.2 Product and Service Offerings
    • 7.10.3 Key Financial Summary
  • 7.11 Intuitive Surgical Inc.
    • 7.11.1 Business Overview
    • 7.11.2 Product and Service Offerings
    • 7.11.3 Key Financial Summary
  • 7.12 ViewRay Inc.
    • 7.12.1 Business Overview
    • 7.12.2 Product and Service Offerings
    • 7.12.3 Key Financial Summary
  • 7.13 Provision Healthcare
    • 7.13.1 Business Overview
    • 7.13.2 Product and Service Offerings
  • 7.14 Isoray Inc.
    • 7.14.1 Business Overview
    • 7.14.2 Product and Service Offerings
    • 7.14.3 Key Financial Summary
  • 7.15 Theragenics Corporation
    • 7.15.1 Business Overview
    • 7.15.2 Product and Service Offerings

Chapter 8. Appendix

  • 8.1 Abbreviations
  • 8.2 Sources and References
  • 8.3 Related Reports

LIST OF TABLES

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 RADIATION - CLINICAL TRIAL - 1
  • TABLE 3 RADIATION - CLINICAL TRIAL - 2
  • TABLE 4 RADIATION - CLINICAL TRIAL - 3
  • TABLE 5 RADIATION - CLINICAL TRIAL - 4
  • TABLE 6 RADIATION - CLINICAL TRIAL - 5
  • TABLE 7 RADIATION - CLINICAL TRIAL - 6
  • TABLE 8 RADIATION - CLINICAL TRIAL - 7
  • TABLE 9 RADIATION - CLINICAL TRIAL - 8
  • TABLE 10 SURGERY - CLINICAL TRIAL - 1
  • TABLE 11 SURGERY - CLINICAL TRIAL - 2
  • TABLE 12 SURGERY - CLINICAL TRIAL - 3
  • TABLE 13 SURGERY - CLINICAL TRIAL - 4
  • TABLE 14 SURGERY - CLINICAL TRIAL - 5
  • TABLE 15 SURGERY - CLINICAL TRIAL - 6
  • TABLE 16 SURGERY - CLINICAL TRIAL - 7
  • TABLE 17 HIFU - CLINICAL TRIAL - 1
  • TABLE 18 HIFU - CLINICAL TRIAL - 2
  • TABLE 19 HIFU - CLINICAL TRIAL - 3
  • TABLE 20 HIFU - CLINICAL TRIAL - 4
  • TABLE 21 HIFU - CLINICAL TRIAL - 5
  • TABLE 22 HIFU - CLINICAL TRIAL - 6
  • TABLE 23 HIFU - CLINICAL TRIAL - 7
  • TABLE 24 CRYOTHERAPY - CLINICAL TRIAL - 1
  • TABLE 25 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 26 RESTRAINT FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 27 HIFU - SONABLATE VS AMBLATHERM (SYSTEM SPECIFICATION)
  • TABLE 28 HIFU - SONABLATE VS AMBLATHERM (SAFETY FEATURE)
  • TABLE 29 PREFERECE OF TREATMENT - SURGERY VS RADIATION THERAPY
  • TABLE 30 PROCESS OF TREATMENT - SURGERY VS RADIATION THERAPY
  • TABLE 31 BENEFITS OF TREATMENT- SURGERY VS RADIATION THERAPY
  • TABLE 32 SIDE-EFFECTS AND DRAWBACKS OF TREATMENT- SURGERY VS RADIATION THERAPY
  • TABLE 33 AVERAGE PRICING OF DEVICES
  • TABLE 34 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2014-2019)
  • TABLE 35 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2020-2030)
  • TABLE 36 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2014-2019)
  • TABLE 37 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2020-2030)
  • TABLE 38 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2014-2019)
  • TABLE 39 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2020-2030)
  • TABLE 40 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2014-2019)
  • TABLE 41 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2020-2030)
  • TABLE 42 SONACARE MEDICAL LLC - AT A GLANCE
  • TABLE 43 EDAP TMS SA - AT A GLANCE
  • TABLE 44 EDAP TMS SA - KEY FINANCIAL SUMMARY
  • TABLE 45 PROFOUND MEDICAL CORPORATION - AT A GLANCE
  • TABLE 46 PROFOUND MEDICAL CORPORATION - KEY FINANCIAL SUMMARY
  • TABLE 47 ECKERT & ZIEGLER AG - AT A GLANCE
  • TABLE 48 ECKERT & ZIEGLER AG - KEY FINANCIAL SUMMARY
  • TABLE 49 HEALTHTRONICS INC. - AT A GLANCE
  • TABLE 50 BOSTON SCIENTIFIC CORPORATION - AT A GLANCE
  • TABLE 51 BOSTON SCIENTIFIC CORPORATION - KEY FINANCIAL SUMMARY
  • TABLE 52 ELEKTA AB - AT A GLANCE
  • TABLE 53 ELEKTA AB - KEY FINANCIAL SUMMARY
  • TABLE 54 ACCURAY INCORPORATED - AT A GLANCE
  • TABLE 55 ACCURAY INCORPORATED - KEY FINANCIAL SUMMARY
  • TABLE 56 VARIAN MEDICAL SYSTEMS INC. - AT A GLANCE
  • TABLE 57 VARIAN MEDICAL SYSTEMS INC. - KEY FINANCIAL SUMMARY
  • TABLE 58 BECTON, DICKINSON AND COMPANY - AT A GLANCE
  • TABLE 59 BECTON, DICKINSON AND COMPANY - KEY FINANCIAL SUMMARY
  • TABLE 60 INTUITIVE SURGICAL INC. - AT A GLANCE
  • TABLE 61 INTUITIVE SURGICAL INC. - KEY FINANCIAL SUMMARY
  • TABLE 62 VIEWRAY INC. - AT A GLANCE
  • TABLE 63 VIEWRAY INC. - KEY FINANCIAL SUMMARY
  • TABLE 64 PROVISION HEALTHCARE - AT A GLANCE
  • TABLE 65 ISORAY INC. - AT A GLANCE
  • TABLE 66 ISORAY INC. - KEY FINANCIAL SUMMARY
  • TABLE 67 THERAGENICS CORPORATION - AT A GLANCE

LIST OF FIGURES

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 4 SPLIT OF PRIMARY INFORMATION
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 7 SPLIT OF PRIMARY RESEARCH BY COMPANY AND DESIGNATION
  • FIG 8 DATA TRIANGULATION APPROACH
  • FIG 9 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET SUMMARY
  • FIG 10 BARGAINING POWER OF BUYERS
  • FIG 11 BARGAINING POWER OF SUPPLIERS
  • FIG 12 INTENSITY OF RIVALRY
  • FIG 13 THREAT OF NEW ENTRANTS
  • FIG 14 THREAT OF SUBSTITUTES
  • FIG 15 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET SNAPSHOT
  • FIG 16 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, SHARE & $M (2019)
  • FIG 17 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2014-2030)
  • FIG 18 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2014-2030)
  • FIG 19 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2014-2030)
  • FIG 20 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2014-2030)
  • FIG 21 PRODUCT BENCHMARKING OF KEY PLAYERS
  • FIG 22 EDAP TMS SA - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2019)
  • FIG 23 PROFOUND MEDICAL CORPORATION - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 24 ECKERT & ZIEGLER AG - REVENUE SPLIT BY SEGMENT AND BY GEOGRAPHY (2019)
  • FIG 25 BOSTON SCIENTIFIC CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 26 ELEKTA AB - REVENUE SPLIT BY GEOGRAPHY (2020)
  • FIG 27 ACCURAY INCOPORATED - REVENUE SPLIT BY GEOGRAPHY (2020)
  • FIG 28 VARIAN MEDICAL SYSTEMS INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 29 BECTON, DICKINSON AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 30 INTUITIVE SURGICAL INC. - REVENUE SPLIT PRODUCT AND SERVICE AND GEOGRAPHY (2019)
  • FIG 31 VIEWRAY INC. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 32 ISORAY INC. - REVENUE SPLIT BY GEOGRAPHY (2019)